Illumina embraces Roche
Twelve years after Roches $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1243 entries already.
Twelve years after Roches $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing.
Incyte Corp. has signed a global license agreement for commercialisation of Morphosys AGs anti-CD-19 programme tafasitamab.
In silico clinical trials pioneer Novadiscovery SA has raised 5m in a series A financing led by Swiss Debiopharm Innovation Fund.
Following a 1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised 18.5m in a Series A round led by Advent France Biotechnology and Medicxi.
NorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate.
4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Mercks checkpoint blocker avelumab plus 4SCs HDAC I blocker domatinostat.
Mutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund.
Critical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality.
Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients
Swedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds.